GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nkarta Inc (NAS:NKTX) » Definitions » Change In Prepaid Assets

Nkarta (Nkarta) Change In Prepaid Assets : $1.69 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nkarta Change In Prepaid Assets?

Nkarta's Change In Prepaid Assets for the quarter that ended in Mar. 2024 was $-0.43 Mil. It means Nkarta's Prepaid Assets declined by $0.43 Mil from Dec. 2023 to Mar. 2024 .

Nkarta's Change In Prepaid Assets for the fiscal year that ended in Dec. 2023 was $1.72 Mil. It means Nkarta's Prepaid Assets increased by $1.72 Mil from Dec. 2022 to Dec. 2023 .

Nkarta Change In Prepaid Assets Historical Data

The historical data trend for Nkarta's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nkarta Change In Prepaid Assets Chart

Nkarta Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Prepaid Assets
Get a 7-Day Free Trial -0.46 -3.65 -4.44 -1.49 1.72

Nkarta Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Prepaid Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.41 1.07 0.43 0.62 -0.43

Nkarta Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nkarta Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of Nkarta's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Nkarta (Nkarta) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nkarta Inc (NAS:NKTX) » Definitions » Change In Prepaid Assets
Comparable Companies
INO ANIX IFRX CDXC VXRT THRX PRLD PRQR AADI MNOV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
6000 Shoreline Court, Suite 102, South San Francisco, CA, USA, 94080
Website
https://www.nkartatx.com
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Executives
Paul J Hastings director, officer: See Remarks 61 HARTFORD STREET, SAN FRANCISCO CA 94114
David Shook officer: Chief Medical Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alicia J. Hager officer: Chief Legal Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Ralph Brandenberger officer: Sr. VP, Technical Operations 6000 SHORELINE COURT, SUITE 102, SAN FRANCISCO CA 94080
James Trager officer: Chief Scientific Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alyssa Levin officer: See Remarks 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Nadir Mahmood officer: Chief Business Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Angela Thedinga director C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kanya Rajangam officer: Chief Medical Officer C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900